Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prime-and-trap vaccine
- Development stage
- Preclinical
- Lead developer
- University of Washington
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular, Intravenous
01
Overview
The **prime-and-trap vaccine** is an experimental, preclinical heterologous malaria vaccine strategy designed to induce durable, protective liver-resident memory CD8+ T (Trm) cells. Developed by the University of Washington, MalarVx, and HDT Bio, the two-step regimen first primes the immune system with a nucleic acid vaccine (either DNA or self-replicating RNA, the latter formulated in HDT Bio's LION cationic nanocarrier) encoding the Plasmodium circumsporozoite protein (CSP). The second step delivers a single 'trapping' dose of radiation-attenuated sporozoites (RAS) that home to the liver, attracting and trapping the primed CD8+ T cells there to eliminate liver-stage Plasmodium parasites and provide sterile protection. Preclinical studies in mice have demonstrated high levels of sterilizing protection, and efforts are underway to translate the strategy to human clinical trials.
- Other names
- prime-and-trap malaria vaccineprime-and-trap regimenprime-and-trap strategy
02
Targets
CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on prime-and-trap vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prime-and-trap vaccine.